These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27612418)

  • 1. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
    Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
    Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice.
    Greenspan EJ; Nichols FC; Rosenberg DW
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1187-97. PubMed ID: 20716632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
    Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
    Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon.
    Mladenova D; Daniel JJ; Dahlstrom JE; Bean E; Gupta R; Pickford R; Currey N; Musgrove EA; Kohonen-Corish MR
    Gut; 2011 Mar; 60(3):350-60. PubMed ID: 20980345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
    Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
    Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multistage vector delivery of sulindac and silymarin for prevention of colon cancer.
    Scavo MP; Gentile E; Wolfram J; Gu J; Barone M; Evangelopoulos M; Martinez JO; Liu X; Celia C; Tasciotti E; Vilar E; Shen H
    Colloids Surf B Biointerfaces; 2015 Dec; 136():694-703. PubMed ID: 26513752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC.
    Faux MC; Weinstock J; Gogos S; Prato E; Azimpour AI; O'Keefe R; Cathcart-King Y; Garnham AL; Ernst M; Preaudet A; Christie M; Putoczki TL; Buchert M; Burgess AW
    Cancer Res Commun; 2022 Feb; 2(2):66-77. PubMed ID: 36860494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
    Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
    Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations.
    Yang K; Fan K; Kurihara N; Shinozaki H; Rigas B; Augenlicht L; Kopelovich L; Edelmann W; Kucherlapati R; Lipkin M
    Carcinogenesis; 2003 Mar; 24(3):605-11. PubMed ID: 12663524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
    Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
    Chiu CH; McEntee MF; Whelan J
    Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
    Ma H; Brosens LAA; Elias SG; Morsink FHM; Nijman IJ; Hylind LM; Montgomery EA; Offerhaus GJA; Giardiello FM; de Leng WWJ
    Sci Rep; 2017 Sep; 7(1):11972. PubMed ID: 28931879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis.
    Femia AP; Soares PV; Luceri C; Lodovici M; Giannini A; Caderni G
    BMC Cancer; 2015 Sep; 15():611. PubMed ID: 26335331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac in familial adenomatous polyposis.
    Levy R
    N Engl J Med; 2002 Aug; 347(8):615. PubMed ID: 12192027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.